Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03543670 | Evaluation of Oncoxin-Viusid® in Prostate Cancer | completed | Phase 2 | 25 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT00728663 | Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 35 | Swiss Cancer InstituteOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT02744534 |
| Targeted Fusion Biopsy of the Prostate |
| completed |
| Phase 2 |
| 21 |
| Emory UniversityOTHER |
| 1 |
| May 8, 2019 |
| clinicaltrials |
| NCT03573011 | PSMA PET/CT for Prostate Cancer(NGP2) | completed | Phase 2 | 64 | University Hospital, GhentOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT00528866 | Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | completed | Phase 2 | 80 | Radiation Therapy Oncology GroupNETWORK | 2 | Apr 24, 2019 | clinicaltrials |
| NCT00348595 | Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer | completed | Phase 1 / Phase 2 | 77 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT03081481 | Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer | completed | Phase 2 | 38 | Sophiris Bio CorpINDUSTRY | 2 | Apr 10, 2019 | clinicaltrials |
| NCT00642018 | A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer | completed | Phase 2 | 154 | Eli Lilly and CompanyINDUSTRY | 4 | Apr 3, 2019 | clinicaltrials |
| NCT00274287 | GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere | completed | Phase 2 | 15 | Oncology Specialists, S.C.OTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT01717391 | [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers | completed | Phase 2 | 36 | John M. BuattiOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT01927627 | Enzalutamide in Patients With High-risk Prostate Cancer | completed | Phase 2 | 42 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01487863 | Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 2 | 69 | DendreonINDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01685983 | A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer | completed | Phase 2 | 82 | Janssen Research & Development, LLCINDUSTRY | 2 | Mar 15, 2019 | clinicaltrials |
| NCT01304485 | PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma | completed | Phase 2 | 2,000 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01530269 | C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma | completed | Phase 2 | 300 | Phoenix Molecular ImagingOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01553188 | AMG 386 and Abiraterone for Advanced Prostate Cancer | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01677897 | Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients(MetAb-Pro) | completed | Phase 2 | 25 | Kantonsspital GraubündenOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00570700 | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | completed | Phase 2 | 38 | University of California, IrvineOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT00311623 | Sirolimus Before Surgery in Treating Patients With Advanced Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT00480090 | A Phase II Study of Ara-C (Cytarabine) in Men With Androgen Independent Prostate Cancer(SLAP) | completed | Phase 2 | 10 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01120470 | OGX-427 in Castration Resistant Prostate Cancer Patients | completed | Phase 2 | 74 | British Columbia Cancer AgencyOTHER | 2 | Feb 15, 2019 | clinicaltrials |
| NCT02507427 | Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study) | completed | Phase 1 / Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03001895 | Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer | completed | Phase 2 | 120 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT00022399 | Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer | completed | Phase 2 | 73 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01257425 | Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg(PAMIS) | completed | Phase 2 | 109 | IpsenINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT02012920 | A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 200 | Innocrin PharmaceuticalINDUSTRY | 4 | Feb 1, 2019 | clinicaltrials |
| NCT02361086 | A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 21 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02445976 | Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. | completed | Phase 2 | 197 | Innocrin PharmaceuticalINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01664923 | Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer(STRIVE) | completed | Phase 2 | 396 | PfizerINDUSTRY | 1 | Jan 30, 2019 | clinicaltrials |
| NCT02409212 | Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer(PANTERA) | completed | Phase 2 | 50 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT01808222 | FACBC for Recurrent Prostate Cancer | completed | Phase 2 | 25 | David M. Schuster, MDOTHER | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01148069 | Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers(TARGET) | completed | Phase 2 | 63 | Rennes University HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02047253 | Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment | completed | Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01832259 | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection | completed | Phase 2 | 30 | University of UtahOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT00450463 | Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT00499408 | Vitamin D and Soy Supplements in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 26 | Wake Forest University Health SciencesOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT00038181 | Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02107430 | Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer | completed | Phase 2 | 62 | SOTIO a.s.INDUSTRY | 1 | Nov 14, 2018 | clinicaltrials |
| NCT00038246 | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00384839 | Vidaza to Restore Hormone Thx Prostate | completed | Phase 2 | 36 | US Oncology ResearchINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00599313 | Phase II Sunitinib Prog Met AIPC | completed | Phase 2 | 36 | US Oncology ResearchINDUSTRY | 1 | Oct 25, 2018 | clinicaltrials |
| NCT01981122 | A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 52 | DendreonINDUSTRY | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01091103 | Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide | completed | Phase 2 | 60 | PfizerINDUSTRY | 1 | Oct 23, 2018 | clinicaltrials |
| NCT01547299 | Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer | completed | Phase 2 | 52 | PfizerINDUSTRY | 2 | Oct 23, 2018 | clinicaltrials |
| NCT01620710 | Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes(PRIAMOS) | completed | Phase 2 | 80 | Heidelberg UniversityOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02153918 | Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Oct 12, 2018 | clinicaltrials |
| NCT00942578 | A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00436956 | AZD2171 to Treat Prostate Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00634647 | Satraplatin and Prednisone to Treat Prostate Cancer | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
Data updated 23 days agoSource updated May 22, 2019source: clinicaltrials